Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DMKG40
|
|||
| Drug Name |
SAR443579
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60; ICD-9: 205] | Phase 1 | [1] | |
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cell division cycle protein 123 (CDC123) | Target Info | . | [2] |
| Natural cytotoxic triggering receptor 1 (NCR1) | Target Info | . | [2] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05086315) An Open-label, First-in-human, Dose-escalation/Expansion Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Adult and Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Sanofi | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.